These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32681021)

  • 1. Engineered CRISPR/Cas9 enzymes improve discrimination by slowing DNA cleavage to allow release of off-target DNA.
    Liu MS; Gong S; Yu HH; Jung K; Johnson KA; Taylor DW
    Nat Commun; 2020 Jul; 11(1):3576. PubMed ID: 32681021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinated Actions of Cas9 HNH and RuvC Nuclease Domains Are Regulated by the Bridge Helix and the Target DNA Sequence.
    Babu K; Kathiresan V; Kumari P; Newsom S; Parameshwaran HP; Chen X; Liu J; Qin PZ; Rajan R
    Biochemistry; 2021 Dec; 60(49):3783-3800. PubMed ID: 34757726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
    Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
    Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
    Kleinstiver BP; Pattanayak V; Prew MS; Tsai SQ; Nguyen NT; Zheng Z; Joung JK
    Nature; 2016 Jan; 529(7587):490-5. PubMed ID: 26735016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR-Cas9 variants.
    Murugan K; Suresh SK; Seetharam AS; Severin AJ; Sashital DG
    Nucleic Acids Res; 2021 Apr; 49(7):4037-4053. PubMed ID: 33744974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
    Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
    PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into a high fidelity variant of SpCas9.
    Guo M; Ren K; Zhu Y; Tang Z; Wang Y; Zhang B; Huang Z
    Cell Res; 2019 Mar; 29(3):183-192. PubMed ID: 30664728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Insights Revealed by the Kinetic Mechanism of CRISPR/Cas9.
    Raper AT; Stephenson AA; Suo Z
    J Am Chem Soc; 2018 Feb; 140(8):2971-2984. PubMed ID: 29442507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single molecule analysis of effects of non-canonical guide RNAs and specificity-enhancing mutations on Cas9-induced DNA unwinding.
    Okafor IC; Singh D; Wang Y; Jung M; Wang H; Mallon J; Bailey S; Lee JK; Ha T
    Nucleic Acids Res; 2019 Dec; 47(22):11880-11888. PubMed ID: 31713616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of improved specificity of engineered Cas9s revealed by single-molecule FRET analysis.
    Singh D; Wang Y; Mallon J; Yang O; Fei J; Poddar A; Ceylan D; Bailey S; Ha T
    Nat Struct Mol Biol; 2018 Apr; 25(4):347-354. PubMed ID: 29622787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA stretching induces Cas9 off-target activity.
    Newton MD; Taylor BJ; Driessen RPC; Roos L; Cvetesic N; Allyjaun S; Lenhard B; Cuomo ME; Rueda DS
    Nat Struct Mol Biol; 2019 Mar; 26(3):185-192. PubMed ID: 30804513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.
    Jain S; Xun G; Abesteh S; Ho S; Lingamaneni M; Martin TA; Tasan I; Yang C; Zhao H
    ACS Synth Biol; 2021 Jun; 10(6):1320-1327. PubMed ID: 34006094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the stability of the SpCas9-DNA complex after cleavage.
    Aldag P; Welzel F; Jakob L; Schmidbauer A; Rutkauskas M; Fettes F; Grohmann D; Seidel R
    Nucleic Acids Res; 2021 Dec; 49(21):12411-12421. PubMed ID: 34792162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Massively parallel kinetic profiling of natural and engineered CRISPR nucleases.
    Jones SK; Hawkins JA; Johnson NV; Jung C; Hu K; Rybarski JR; Chen JS; Doudna JA; Press WH; Finkelstein IJ
    Nat Biotechnol; 2021 Jan; 39(1):84-93. PubMed ID: 32895548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bidirectional Degradation of DNA Cleavage Products Catalyzed by CRISPR/Cas9.
    Stephenson AA; Raper AT; Suo Z
    J Am Chem Soc; 2018 Mar; 140(10):3743-3750. PubMed ID: 29461055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered ScCas9 with broad PAM range and high specificity and activity.
    Chatterjee P; Jakimo N; Lee J; Amrani N; Rodríguez T; Koseki SRT; Tysinger E; Qing R; Hao S; Sontheimer EJ; Jacobson J
    Nat Biotechnol; 2020 Oct; 38(10):1154-1158. PubMed ID: 32393822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.
    Chen JS; Dagdas YS; Kleinstiver BP; Welch MM; Sousa AA; Harrington LB; Sternberg SH; Joung JK; Yildiz A; Doudna JA
    Nature; 2017 Oct; 550(7676):407-410. PubMed ID: 28931002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive UHPLC- and CE-based methods for engineered Cas9 characterization.
    Camperi J; Console G; Zheng L; Stephens N; Montti M; Roper B; Zheng M; Moshref M; Dagdas Y; Holder P; Stella C
    Talanta; 2023 Jan; 252():123780. PubMed ID: 35988299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Structure-based optimization and design of CRISPR protein xCas9].
    Xue D; Zhu H; Du W; Tang H; Huang Q
    Sheng Wu Gong Cheng Xue Bao; 2021 Apr; 37(4):1385-1395. PubMed ID: 33973451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.